Emil Bujak

HBM Partners AG (Investment Management) (HBM-IM) is the asset management division of HBM Partners AG. The firm is headquartered in Zug and was founded in 2001. HBM-IM provides investment advisory services to private companies. They manage the fund HBM Healthcare Investments.

Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ.

Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO.

NYU Elaine A. & Kenneth G. Langone Medical Center provides health care services. It offers treatments for bone, joint, and muscle disorders; brain and nervous system disorders cancers, tumors and blood disorders; genetic and chromosomal disorders and immune system disorders. The company was founded in 1841 and is headquartered in New York, NY.

Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Shape Memory Medical, Inc. develops, manufactures and wholesales novel peripheral vascular and neurovascular embolization devices. The company was founded by Alan R. Pelton and is headquartered in Santa Clara, CA.

Vascular Dynamics, Inc. provides blood pressure modulation devices. It develops and commercializes a passive, catheter-delivered implant for the treatment of hypertension. The company was founded in 2008 and is headquartered in Mountain View, CA.

Gebrüder Meier AG is a company based in Regensdorf, Switzerland. The Swiss company provides repair services for electric motors and frequency converters. Part of ERNE AG Bauunternehmung, Gebrüder Meier AG was founded in 1998. Daniel G. Zeidler has been the CEO of the company since 2022.

Dren Bio, Inc. operates as a biotechnology company. It focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents. The company was founded by John Wesley and Nenad Tomasevic in 2019 and is headquartered in San Carlos, CA.

River 2 Renal Corp. develops novel therapies targeting orphan diseases in the renal space. The private company is based in New York, NY.

Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services.

Reha Technology AG designs, manufactures and distributes robotic-assisted systems for neuro-rehabilitation. Its products include G-EO system, nexstep, first mover and armotion. The company was founded in 2011 and is headquartered in Olten, Switzerland.

MiCardia Corp. designs, develops, and commercializes implantable medical devices. The firm offers implantable devices for the treatment of heart diseases, such as mitral valve regurgitation and congestive heart failure. It also provides enCor, an annuloplasty device that corrects residual mitral regurgitation on a beating heart. The company was founded in November 2004 by Michael R. Henson, Shawn Moaddeb and Samuel M. Shaolian and is headquartered in Irvine, CA.

ValCare Medical, Inc. engages in the designing, developing and commercializing devices and accessories for minimally invasive treatment of heart valve diseases. The firm develops a unique transcatheter device, which will provide the capability to implant the mitral annuloplasty device interventionally without surgery. The company was founded by Samuel M. Shaolian in 2012 and is headquartered in Herzlyia Pituach, Israel.

Bank Julius Bär & Co. AG (BJB) is the private banking subsidiary of Julius Bär Gruppe AG (SWX: BAER) in Switzerland. Headquartered in Zurich, BJB was founded in 1890 and provides personal wealth management advice to private clients and family offices.

Part of Boston Scientific Corp., Schneider (Europe) GmbH is a Swiss company that makes stents used to prop open arteries and other devices for angioplasty. The company is based in Bulach, Switzerland. Schneider (Europe was acquired by Boston Scientific Corp. from Pfizer Inc. on September 10, 1998 for $2,100 million.

Ellipse Technologies, Inc. develops and commercializes implants for spinal and orthopedic applications. It designs, develop and commercialize non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. The company was founded by Samuel M. Shaolian and Shawn Moaddeb on June 30, 2005 and is headquartered in Aliso Viejo, CA.

Tensys Medical, Inc. develops blood pressure monitoring systems. The firm provides patient safety by designing, and manufacturing continuous, non-invasive hemodynamic monitoring systems. The company was founded in 1995 and is headquartered in San Diego, CA.

HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA.

EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy.

ConnectRN, Inc. operates as a mobile technology company connecting hospitals with available nurses. Its platform provides various tools to connect healthcare providers to qualified and available staff via an alert system that is sent to their mobile devices. The company is headquartered in Brookline, MA.

Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017.